de Jong, Vincent M. T.
Pruntel, Roelof
Steenbruggen, Tessa G.
Bleeker, Fonnet E.
Nederlof, Petra
Hogervorst, Frans B. L.
linn, Sabine C.
Article History
Received: 17 February 2022
Accepted: 2 June 2022
First Online: 16 September 2022
Declarations
:
: SCL reports grants from ZonMw, the Dutch Cancer Society, and A Sister’s Hope during the conduct of the study. SCL is an advisory board member for Cergentis, and IBM, and received institutional research support from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, Novartis, Pfizer, Roche, Tesaro, and Immunomedics. In addition, SCL received institutional non-financial support from AstraZeneca, Genentech, Novartis, Roche, Tesaro, and Immunomedics and institutional educational financial support from Bayer and Daiichi-Sankyo outside of this study. All other authors declare no competing interest.
: The study was approved by the institutional research board of the Netherlands Cancer Institute (IRBdm19-106). All (retrospective) medical data/biospecimen studies at the Netherlands Cancer Institute have been executed pursuant to Dutch legislation and international standards. Prior to 25 May 2018, national legislation on data protection applied, as well as the International Guideline on Good Clinical Practice. From 25 May 2019 we also adhere to the GDPR. Within this framework, patients are informed and have always had the opportunity to object or actively consent to the (continued) use of their personal data & biospecimens in research. Hence, the procedures comply both with (inter-) national legislative and ethical standards. Patients included in clinical trials have given written informed consent.